Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Amgen Blood Cancer Drug Meets Primary Endpoint In Late-Stage Study

RELATED NEWS
Trade AMGN now with 

Amgen Inc. (AMGN: Quote) Monday said its blood cancer drug Kyprolis in combination with two other drugs helped patients live significantly longer compared to standard treatment.

The California-based drug giant said patients with relapsed multiple myeloma when treated with Kyprolis in combination with Revlimid and low-dose dexamethasone lived 8.7 months longer without disease worsening compared to patients treated with only Revlimid and low-dose dexamethasone.

Multiple myeloma is the second most common hematologic cancer that results from an abnormality of plasma cells, usually in the bone marrow. In the US, about 70,000 people are living with multiple myeloma and around 24,000 new cases are diagnosed annually.

The FDA had granted accelerated approval of Kyprolis for the treatment of patients with multiple myeloma in 2012. Kyprolis is marketed in the US by Amgen's subsidiary Onyx Pharmaceuticals Inc.

The study called Aspire was conducted on 792 patients. Amgen said patients treated with Kyprolis lived for a median of 26.3 months without disease worsening, a significant improvement compared to the 17.6 months in patients who received standard treatment.

Chief Executive Robert Bradway said "Our mission at Amgen is to serve patients by advancing medicines that address serious disease. Kyprolis is an important building block in our robust, differentiated pipeline."

AMGN is currently trading at $126.84, up $1.29 or 1.03%, on the Nasdaq.

Register
To receive FREE breaking news email alerts for Amgen Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Stocks moved notably higher over the course of the trading day on Friday after initially showing a lack of direction. The gains on the day extended the recent upward trend by the markets, with the tech-heavy Nasdaq reaching its best closing level in almost a month. Looking to capitalize on news of an Ebola diagnosis in New York City, Republican Senate candidate Scott Brown issued a statement Friday criticizing his Democratic opponent Sen. Jeanne Shaheen, D-N.H., for "waffling" on a travel ban. In another troubling sign for Democrats, the results of a Gallup poll released on Friday show that Tea Party Republicans are much more motivated to vote in the upcoming midterm elections than other Americans. The poll found that 73 percent of Tea Party Republicans are "extremely" or "very" motivated to vote in this year's elections.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.